Stock Ratings / Health Care / IMRN / dividends

UPC (33) CURX (34) KPRX (30) TCRT (36) ⌘ Pro Terminal →

Immuron Limited (IMRN) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.88 -4.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.87

Immuron Limited (IMRN) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $7.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IMRN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IMRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Immuron Limited (NASDAQ: IMRN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.88 (-4.60% 1D, market cap $7.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IMRN ranks #362 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IMRN compare to UPC and CURX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMRN carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, UPC (Universe Pharmaceuticals Inc. (Class A)) holds a E grade (33/100 RQD, P/E N/A, ROIC —, cap $7.7M) and CURX (Curanex Pharmaceuticals Inc) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $7.7M). Among the 5-stock peer group, IMRN leads on earnings multiple (N/A) while CURX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IMRN?

▼

For Immuron Limited (IMRN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #362 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.87 (-1.02%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMRN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY IMRN SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($208.5K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$1.04-7.7% Next Q

Q2 (-2Q)

Grade C-$0.96-4.2% Next Q

Q3 (-1Q)

Grade C-$0.92-4.3% Next Q

Current

Grade D$0.88-5.9% Hist 90D α

Trajectory: C (55) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IMRN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IMRN currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.15) and Max Pain ($0.92) forces dealer call-delta covering toward $2.10.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMRN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IMRN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMRN)

✓Walkthrough of IMRN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IMRN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +8.64%🛡️ HOLDING TREND SUPPORT

2026-11-02O $0.90H $0.92L $0.88C $0.88VOL 3.1K

RES: $2.22SUP: $0.85SMA50: $1.15SMA200: $1.01

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMRN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMRN Butterfly Map → + Track IMRN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IMRN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMRN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IMRN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMRN)

Health Care Rank #362 of 1016 ⚔️ UPC vs IMRN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMRN vs. UPC, CURX, KPRX, TCRT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Immuron Limited (IMRN) ranks #362 by composite RQD confidence (47/100, grade D) and #918 by equity capitalization ($7.4M). Within this direct 5-issuer industry benchmark cohort, IMRN leads on earnings valuation at N/A trailing P/E, while CURX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IMRN currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IMRN ACTIVE Immuron Limited	D	47/100	—	—	—	-4.60%	$7.4M	Benchmark Subject
UPC Universe Pharmaceuticals Inc. (Class A)	E	33/100	—	35.3%	—	-3.25%	$7.7M	/upc-vs-imrn →
CURX Curanex Pharmaceuticals Inc	E	34/100	—	—	-35.0%	+4.45%	$7.7M	/curx-vs-imrn →
KPRX Kiora Pharmaceuticals Inc.	E	30/100	—	—	-35.0%	-11.36%	$7.8M	/kprx-vs-imrn →
TCRT Alaunos Therapeutics Inc.	D-	36/100	—	—	-35.0%	+3.18%	$7.8M	/tcrt-vs-imrn →

2. IMRN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Immuron Limited (IMRN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $7.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. IMRN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IMRN compare to UPC and CURX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IMRN?

Where is IMRN trading relative to its 50-day, 200-day, and 52-week technical levels?

IMRN last traded at $0.88 (-4.60% on volume of 12,779 shares), positioning the stock -23.48% below its 50-day simple moving average ($1.15) and -12.87% below its 200-day simple moving average ($1.01). Across its 52-week range of $0.68 to $2.00, IMRN sits at the 15.2% percentile with a 14-day RSI of 38.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.99).

IMRN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does IMRN pay a dividend and is it safe?

Immuron Limited (IMRN) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: IMRN RQD Cockpit IMRN 12M Forecast IMRN Earnings & Move IMRN Dividends & DRIP IMRN Insiders & 13F IMRN Whale Options IMRN Profit Sankey IMRN News & Why

ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IMRN — Immuron Limited: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:20:19Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, IMRN scores 47 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 12 / 20 (ROIC 0%; FCF yield 0%); Whale 13F Flow at 4 / 20 (institutional accumulation and options positioning); Insider Conviction at 9 / 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 9 / 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillar is institutional flow at 4 of 20, and the cash engine pillar reflects zero reported return on invested capital and zero free cash flow yield. The forensic pillar is the relative strength, supported by an Altman Z of 2.5, a Piotroski F of 6 out of 9, and a Debt/Equity of 0.5. For a prospective investor, the rating implies that the current profile offers limited evidence of cash generation and weak institutional support, so the upside case depends on developments the source data does not establish. This is educational analysis, not personalized advice.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links. Not available in source data for upstream suppliers, downstream customers, or sector correlations. The graph provides no basis for identifying 2nd-order bottlenecks. The investor-relevant observation is that the North American sales decline noted in the news wire, if it reflects a concentrated channel, is not mapped in the source data to any named counterparty.

Open Questions

What are the reported revenue, operating income, net income, and free cash flow figures, given that the financials section is empty?
What is the size and composition of the North American sales decline cited in the Q1 wire item, and what drove the global sales increase?
What is the company's product portfolio and principal customer base?
What capital runway or cash position supports operations at a $7.4M market capitalization?
Which institutional and insider holders drove the 4/20 whale-flow and 9/20 insider-conviction pillar scores?

IMRN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Immuron Limited (IMRN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IMRN Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 15h ago

Immuron continued quarterly sales growth

Yahoo Finance report covering Immuron Limited (IMRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 18h ago

Immuron Limited (IMRN) Slips 4.66% to $0.98 as Shares Test Lower Support Zone - Equal Weight ETF

https://www.siam.in/ report covering Immuron Limited (IMRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 21h ago

Alterity Therapeutics Limited (ATHE) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Immuron Limited (IMRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Q1 global sales rose 9%, but North American sales fell at Immuron (IMRN).

Stock Titan report covering Immuron Limited (IMRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Immuron (IMRN) Slips 1.83% to $1.07 as Shares Drift Toward Lower Support - IV Crush Alert

https://www.dars.gov.et/ report covering Immuron Limited (IMRN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo • 6d ago

Presenting on Emerging Growth Conference 97 Day 1 on October 28; Register to live stream

MIAMI, Oct. 27, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 97th Emerging Growth Conference on October 28 & 29, 2026. The Emerging Growth Confere

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 11d ago

Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference

MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Emerging Growth Conferenc

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 20d ago

Travelan® Phase 2 Study Results Published

MELBOURNE, Australia, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the Nature Jou

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IMRN Bull vs. Bear Conversation Board — What's Your Call at $0.88?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMRN 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $0.99 (+7.6%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IMRN (D • RQD 47/100) a Buy at $0.92?

Welcome to the IMRN (Immuron Limited) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.76 (-17.4%)

Spot @ $0.92

Pump the brakes on IMRN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IMRN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Immuron Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.10 (+19.6%)

Spot @ $0.92

IMRN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IMRN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.92 (52-wk range $0.68 - $2.00), any beat on forward guidance forces shorts and underweight funds to chase.